Core Viewpoint - The company has obtained the domestic production drug registration certificate for Dydrogesterone tablets as of May 2025 and has also established its own production capability for Dydrogesterone raw materials [1] Group 1 - The company announced on September 17 that it has received the registration certificate for Dydrogesterone tablets [1] - The company is now capable of independently producing Dydrogesterone raw materials [1]

Core Viewpoint - The company has confirmed its capability to independently produce the active pharmaceutical ingredient (API) for Dydrogesterone, having obtained the production registration certificate for Dydrogesterone tablets in May 2025 [1] Group 1 - The company has a strong accumulation of experience and technical advantages in the field of steroid raw materials [1] - The company has received the domestic production registration certificate for Dydrogesterone tablets, with the announcement number 2025-023 [1] - The company possesses the independent production capability for Dydrogesterone API [1]